{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:47:21Z","timestamp":1792032441408,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4966,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1093\/annonc\/mdj992","type":"journal-article","created":{"date-parts":[[2006,5,15]],"date-time":"2006-05-15T17:27:50Z","timestamp":1147714070000},"page":"iv12-iv14","source":"Crossref","is-referenced-by-count":23,"special_numbering":"S4","title":["Mantle cell lymphoma: an update on management"],"prefix":"10.1016","volume":"17","author":[{"given":"A.D.","family":"Zelenetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdj992_bb0010","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Fernandez","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj992_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(03)13868-8","article-title":"Non-Hodgkin\u2019s lymphoma","volume":"362","author":"Evans","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdj992_bb0020","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1200\/JCO.2005.55.017","article-title":"Current treatment approaches for mantle-cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj992_bb0025","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.bmt.1705080","article-title":"Stem cell transplantation for mantle cell lymphoma: if, when and how?","volume":"36","author":"Kiss","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdj992_bb0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2003.12.002","article-title":"Integrating monoclonal antibodies into the management of mantle cell lymphoma","volume":"31","author":"Berinstein","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdj992_bb0035","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1586\/14760584.3.2.163","article-title":"The role of idiotype vaccines in the treatment of human B-cell malignancies","volume":"3","author":"Bendandi","year":"2004","journal-title":"Expert Rev Vaccines"},{"key":"10.1093\/annonc\/mdj992_bb0040","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj992_bb0045","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj992_bb0050","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj992_bb0055","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood.V104.11.1388.1388","article-title":"Phase II study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphomas: a Wisconsin Oncology Network Study","volume":"104","author":"Kahl","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj992_bb0060","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdj992_bb0065","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1182\/blood.V104.11.2632.2632","article-title":"A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) for treatment of patients with relapsed and refractory mantle cell lymphoma","volume":"104","author":"Oki","year":"2004","journal-title":"Blood"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdj992_bb0070","first-page":"54","article-title":"Sequential rituximab with tositumomab\/I131 tositumomab followed by CHOP chemotherapy is a safe and highly effective regimen","volume":"16","author":"Zelenetz","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdj992_bb0075","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"23","author":"O\u2019Connor","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj992_bb0080","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdj992_bb0085","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdj992_bb0090","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1007\/s00280-003-0624-x","article-title":"Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms","volume":"52","author":"Senderowicz","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdj992_bb0095","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","article-title":"Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group","volume":"21","author":"Kouroukis","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419413653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419413653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/17\/suppl_4\/iv12\/436210\/mdj992.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T07:51:52Z","timestamp":1627372312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419413653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":18,"alternative-id":["S0923753419413653"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdj992","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}